Company successfully transitioned to commercial stage with first revenue generation ($3.9M), FDA-approved product launch, established nationwide distribution, and initiated patient treatment. However, positive sentiment is tempered by significant net losses and low cash reserves.
Successfully launched LYMPHIR with FDA approval, achieved initial nationwide distribution, deployed AI-enabled commercial platform, and secured international patient access agreements. Early physician adoption is underway with patients receiving treatment at leading cancer centers. Management estimates market exceeds $400M with strong intellectual property protections.
Articles that tag CTOR but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
